Risk-based lung cancer screening may prevent more deaths than current guidelines
1. In terms of early lung cancer death per individual screened, targeting lung cancer mortality risk may improve lung cancer screening efficiency.
2. However, the increases in efficiency were attenuated when measured by life-years, quality-adjusted life-years (QALYs), and cost-effectiveness.
Study Rundown: Current guidelines for lung cancer screening using low-dose computed tomography (LDCT) do not take into consideration long-term survival differences or cost differences between higher- and lower-risk patients. This cost-effectiveness analysis calculated the value of individualized risk-based criteria for lung cancer screening in comparison to the National Lung Screening Trial (NLST) eligibility criteria. Using NLST data, researchers stratified 53 086 participants according to their baseline risk for lung cancer mortality. Using a multistate prediction model, the authors found that targeting risk may improve the efficiency of screening when measured by early lung cancer death per individual screened. However, the increases in efficiency were attenuated when measured by life-years, QALYs, and cost-effectiveness. Considering that high-risk patients cost more to screen and have a reduced life expectancy after any lung cancer survival, the authors suggested that using a risk model is not likely to result in considerable improvement in the cost-effectiveness of lung cancer screening using LDCT (as measured by QALYs gained compared to cost).
A strength of this study is that it takes into consideration differences in long-term survival of lung cancer and quantifies the cost differences between higher- and lower-risk patients. A limitation of this study is that the study design does not take into account all associated differences between the risk of mortality from lung cancer and quality of life.
In-Depth [cost-effective analysis]: Using data from the NLST regarding 53 086 participants, researchers stratified the participants into deciles based on their 7-year risk of lung cancer mortality. Researchers used a multistate prediction model to measure several outcomes for LDCT compared to chest radiography for each decile. The researchers found that participants who had a higher risk of death from lung cancer were older, had more comorbidities, and had increased costs related to screening. For the first 7 years, 1.2 (lowest risk decile) to 9.5 (highest risk decile) deaths due to lung cancer were prevented per 10 000 person-years. Across risk groups, the gradient of benefits was lessened when measured in life-years and QALYs, and the incremental cost-effectiveness ratios (ICERs) were comparable. The ICER was $75 000 per QALY and $53 000 per QALY for the lowest and highest risk deciles, respectively. Participants willing to spend $100 000 per QALY would obtain LDCT screening for all deciles.
©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
Sign Up for Free e-newsletters
- Leukemia Risk in Children, Maternal Use of Hormonal Contraception Linked in Population Study
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Molecular Features May Predict Response in Primary Pancreatic Cancer
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Clinical Characteristics That Increase Risk of Chemotherapy-Induced Febrile Neutropenia Identified
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Counseling Patients on Oral Chemotherapy
- Patients and Caregivers Worry About Cost of Cancer Care
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|